Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. Th ...
Seeking Alpha

Belay Diagnostics Announces US Commercial Launch of Summit™: Breakthrough CSF Testing for CNS Cancer Detection and Management

Validation Data on More Than 100 Patients published in Journal of Molecular Diagnostics CHICAGO, April 25, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the ...
Contract Pharma

Fujirebio Unveils CSF Assay to Assist Alzheimer’s Research

Fujirebio is launching a human cerebrospinal fluid (CSF) assay in its continuing efforts to detect Alzheimer’s ...
Medscape

FDA Clears New Biomarker Assays for Early Alzheimer’s Detection

Roche has received US Food and Drug Administration (FDA) 510(k) clearance for additional cerebrospinal fluid (CSF) assays for Alzheimer’s disease (AD), supporting timely diagnosis and treatment ...

New Finger Prick Blood Test Rivals Brain Scans for Alzheimer’s Diagnosis

A new finger prick test claims to detect Alzheimer’s with 91% accuracy using p-tau217 biomarkers. Learn how this accessible ...

Researchers explore new diagnostic tools, genetic roots for early-onset dementia

Researchers at the new Center for Brain Health at UT Health San Antonio are studying midlife testing for early-onset dementia with blood-based biomarkers to see if they can detect disease activity up ...